Article
A CME Symposium held during the AAO & SOE 2004 Joint Meeting in New Orleans.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Perfuse Therapeutics announces positive results from phase 1/2a trial of PER-001, an intravitreal implant for glaucoma
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Innovent Biologics completes first patient dosing in its phase 2 clinical trial assessing efdamrofusp alfa in patients with DME
Beacon Therapeutics shares 6-month interim safety and efficacy results from Phase 2 DAWN study for XLRP